Clinical trial
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That…
NCT00265876 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00265876 |
|---|---|
| Title | AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery |
| Official title | A Phase I/II Study of AZD0530 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | AZD0530, gemcitabine hydrochloride |
| Enrollment | 34 |
| Start date | Apr 26, 2006 |
| Primary completion | Jan 8, 2009 |
| Completion | Jan 6, 2012 |
| First posted | Dec 15, 2005 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: